ArticleNature communications2025
Plant-derived hydrogel and photosynthetic nano-units for myocardial infarction therapy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Nanoparticle-Based Targeted Drug-Delivery Systems for Cardiomyopathy: Mechanisms and Therapeutic Advances.Molecules (Basel, Switzerland) · 2026Review
- Borrowing sunlight: Photosynthetic bioengineering as an emerging therapeutic paradigm.Clinical and translational medicine · 2026Article
- From targeted delivery to inflammation suppression: engineering plant exosomes for heart failure therapy post-infarction.Materials today. Bio · 2026Article
- Avenues for optimization of cardiac therapeutics by minimally invasive delivery.Acta biomaterialia · 2026Review
- Bioengineering Applications of Chinese Herbal Medicine-Derived Exosomes in Cardiovascular Diseases: Mechanisms and Translational Prospects.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ischemic injury and reperfusion injury collectively determine the total infarct size, a major prognostic factor following myocardial infarction (MI). Therefore, addressing both ischemic and reperfusion stages could substantially reduce infarct size and improve clinical outcomes. In this study, we develop a two-component therapeutic system from different parts of Glycyrrhiza: a functional hydrogel made from glycyrrhizic acid extracted from the stem and root, and nanosized chloroplast units (NCUs) derived from leaves. The hydrogel demonstrates therapeutic effects during both hypoxia and reoxygenation stages in vitro, while the photosynthetic NCUs alleviate hypoxia injury by providing ATP and NADPH under illumination. Subsequent in vivo study reveals the most significant therapeutic effect in the combination group (NCU plus hydrogel), which effectively treats both ischemic and reperfusion stages. Our study highlights the cross-species application of plant photosynthetic mechanisms in MI treatment and confirms that simultaneous treatment of ischemia and reperfusion is more effective than treating either stage alone, offering a promising therapeutic strategy for MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.